TY - CHAP
T1 - Neonatal onset interstitial lung disease as a primary presenting manifestation of mucopolysaccharidosis type I
AU - Bush, Douglas
AU - Sremba, Leighann
AU - Lomax, Kate
AU - Lipsett, Jill
AU - Ketteridge, David
AU - Bratkovic, Drago
AU - Enchautegui-Colon, Yazmin
AU - Weisfeld-Adams, James
AU - Galambos, Csaba
AU - Lummus, Seth
AU - Wartchow, Eric
AU - Weinman, Jason
AU - Liptzin, Deborah R.
AU - Baker, Peter
N1 - Publisher Copyright:
© Society for the Study of Inborn Errors of Metabolism (SSIEM) 2018.
PY - 2019
Y1 - 2019
N2 - We describe two cases of neonatal onset interstitial lung disease eventually diagnosed as mucopolysaccharidosis type I (MPS I). In both cases, evaluation led to lung biopsy, pathology review, and identification of glycogen deposition. Pulmonary interstitial glycogenosis (PIG) was considered as a clinical diagnosis in case one; however, further review of electron microscopy (EM) was more consistent with MPS I rather than PIG. Both cases were confirmed to have MPS I by enzyme and molecular analysis. Neonatal interstitial lung disease is an atypical presentation for MPS I which is likely under-recognized. Diagnosis through clinical guidelines and a multidisciplinary approach had a major impact on patient management. The diagnosis of MPS I prompted timely initiation of enzyme replacement therapy (ERT) and the patients ultimately underwent hematopoietic stem cell transplantation (HSCT) to improve symptomatic outcomes. In addition to treatment, immediate precautionary recommendations were made to avoid potentially catastrophic outcomes associated with cervical instability. These cases add to the clinical spectrum of MPS I in the newborn period. They further illustrate the difficulties in early recognition of the disease, and importance of a definitive diagnosis of MPS I in infants with interstitial lung disease.
AB - We describe two cases of neonatal onset interstitial lung disease eventually diagnosed as mucopolysaccharidosis type I (MPS I). In both cases, evaluation led to lung biopsy, pathology review, and identification of glycogen deposition. Pulmonary interstitial glycogenosis (PIG) was considered as a clinical diagnosis in case one; however, further review of electron microscopy (EM) was more consistent with MPS I rather than PIG. Both cases were confirmed to have MPS I by enzyme and molecular analysis. Neonatal interstitial lung disease is an atypical presentation for MPS I which is likely under-recognized. Diagnosis through clinical guidelines and a multidisciplinary approach had a major impact on patient management. The diagnosis of MPS I prompted timely initiation of enzyme replacement therapy (ERT) and the patients ultimately underwent hematopoietic stem cell transplantation (HSCT) to improve symptomatic outcomes. In addition to treatment, immediate precautionary recommendations were made to avoid potentially catastrophic outcomes associated with cervical instability. These cases add to the clinical spectrum of MPS I in the newborn period. They further illustrate the difficulties in early recognition of the disease, and importance of a definitive diagnosis of MPS I in infants with interstitial lung disease.
KW - Childhood interstitial and diffuse lung disease
KW - Hurler syndrome
KW - MPS I Mucopolysaccharidosis
KW - Pulmonary interstitial glycogenosis
UR - http://www.scopus.com/inward/record.url?scp=85061116177&partnerID=8YFLogxK
U2 - 10.1007/8904_2018_101
DO - 10.1007/8904_2018_101
M3 - Chapter
AN - SCOPUS:85061116177
T3 - JIMD Reports
SP - 71
EP - 77
BT - JIMD Reports
PB - Springer
ER -